Multiple Myeloma

2019 ASCO: Lenalidomide May Reduce the Risk of Smoldering Multiple Myeloma Progressing to Active Disease

A phase III randomized trial (E3A06) by Lonial et al testing the effect of single-agent lenalidomide vs observation in patients with intermediate- or high-risk...

Gastroesophageal Cancer

2019 ASCO: Reduced Chemotherapy Dosages in Elderly Patients With Advanced Gastroesophageal Cancer

A phase III randomized clinical study evaluating the optimum dose of a combination chemotherapy regimen of oxaliplatin and capecitabine...

Breast Cancer

2019 ASCO: Low-Fat Diet May Reduce the Risk of Death From Breast Cancer in Postmenopausal Women

Excluding skin cancer, breast cancer is the most common cancer diagnosed in women in the United States. In 2019, the American Cancer Society estimates that about 268,600...

Solid Tumors
CNS Cancers

2019 ASCO: Entrectinib in Children and Adolescents With Recurrent or Refractory Solid or Central Nervous System Tumors

A phase I/IB study evaluating the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors, including central nervous system...


2019 ASCO: Nearly One-Quarter of Participants in the Pediatric MATCH Trial Have an Actionable Molecular Alteration

A study investigating the frequency of targetable molecular alterations in pediatric cancer among patients enrolled in the National Cancer Institute–Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice (MATCH)...


More Top Stories

Kidney Cancer

Ignacio Duran, MD, PhD, on Renal Cell Carcinoma: Results From the METEOR Trial on Cabozantinib vs Everolimus

Lung Cancer

Local Consolidative Therapy Linked to Survival Benefit in Oligometastatic Non–Small Cell Lung Cancer

A retrospective analysis of nearly 200 patients treated with local consolidative therapy for oligometastatic non–small cell lung cancer (NSCLC) has found improved overall survival associated with aggressive consolidation.1 According to data presented at the 2019 Multidisciplinary Thoracic Cancers...


Impact of Establishment of Cancer Urgent Care Clinic on Emergency Department Visits

In a study reported in the Journal of Oncology Practice, Hong et al found that the establishment of a cancer urgent care clinic slowed the increasing rate of visits to regional emergency departments among adults newly diagnosed with cancer.  Study Details The study involved data on 33,316...

Hepatobiliary Cancer

Ahmed Omar Kaseb, MD, on Liver Cancer: Results From an Immunotherapy Trial

Hematologic Malignancies

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

GUEST EDITORS Dr. Abutalib is Assistant Director, Hematology and Hematopoietic Cell Transplantation Director, Hematopoietic Cell Transplant Apheresis Service, Cancer Treatment Centers of America, Zion, Illinois, Editor-in-Chief, Advances in Cell & Gene Therapy. Dr. Medeiros is Professor...

Cigall Kadoch, PhD, Chosen for 2019 Martin and Rose Wachtel Cancer Research Prize

The American Association for the Advancement of Science and Science Translational Medicine announced that Cigall Kadoch, PhD, has been chosen for the 2019 Martin and Rose Wachtel Cancer Research Prize. Dr. Kadoch is Assistant Professor of Pediatric Oncology at Dana-Farber Cancer Institute;...

FDA Approves Dalteparin Sodium for VTE in Pediatric Patients

On May 16, 2019, the U.S. Food and Drug Administration (FDA) approved dalteparin sodium (Fragmin) to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients 1 month of age and older. This is the first FDA-approved therapy to treat VTE in pediatric patients....

Bladder Cancer

Thomas Powles, MD, PhD, on Urothelial Carcinoma: Results From the RANGE Trial on Ramucirumab and Docetaxel


Umbralisib: Potential Option for Relapsed or Refractory Marginal Zone Lymphoma

UMBRALISIB—an investigational PI3K-delta inhibitor—produced impressive results as monotherapy in patients with relapsed or refractory marginal zone lymphoma, according to an interim analysis of the phase II UNITY-NHL trial presented at the 2019 American Association for Cancer Research (AACR) Annual ...


AUA Releases New Clinical Guideline for Diagnosis and Treatment of Early-Stage Testicular Cancer

Recently, the American Urological Association (AUA) released a new clinical guideline on the diagnosis and treatment of early-stage testicular cancer. Testicular cancer is the most common cancer among men ages 20 to 40. Although it is a less common form of cancer, about 9,600 American men...